- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00011986
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma
Studieoversikt
Status
Detaljert beskrivelse
OBJECTIVES:
Compare the efficacy of paclitaxel and carboplatin with or without gemcitabine, doxorubicin HCl liposome, or topotecan, in terms of overall and progression-free survival, in patients with stage III or IV ovarian epithelial or serous primary peritoneal carcinoma.
Determine the response rate in patients with measurable disease treated with these regimens.
Compare the toxic effects of these regimens in these patients. Compare the complications in patients treated with these regimens. Determine the dose-intensity and cumulative dose delivery for these regimens in these patients.
OUTLINE:
This is a randomized, multicenter study. Patients are stratified into 1 of 3 strata according to extent of residual disease and plans for interval cytoreductive surgery: Stratum A: Optimal (microscopic or macroscopic) residual disease without plans for surgery Stratum B: Suboptimal residual disease without plans for surgery Stratum C: Suboptimal residual disease with plans for surgeryPatients are randomized to 1 of 5 treatment arms. Arm I: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity. Arm II: Patients receive chemotherapy as in arm I and gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues as in arm I. Arm III: Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I. Arm IV: Patients receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy. Arm V: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy. Patients with initial unresectable or suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery between courses 4 and 5 of chemotherapy. Patients are followed every 3 months for 2 years and then every 6 months.
PROJECTED ACCRUAL: Approximately 4,000-5,000 patients (800-1,000 per treatment arm) will be accrued for this study within 3.5-5 years.
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19103
- Gynecologic Oncology Group
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically confirmed stage III or IV ovarian epithelial or serous primaryperitoneal carcinoma
The following are ineligible:
- Germ cell tumors
- Sex cord-stromal tumors
- Carcinosarcomas
- Mixed Mullerian tumors or carcinosarcomas
- Metastatic carcinomas from other sites to theovary
- Low malignant potential tumors, including micropapillary serouscarcinomas
- Mucinous primary peritoneal carcinoma
- Prior ovarian low malignant potential tumor (borderline carcinoma) that was surgically resected with subsequent development of invasive adenocarcinoma allowed if no prior chemotherapy
- Optimal (no greater than 1 cm) or suboptimal residual disease after initial surgery
Prior breast cancer allowed provided the following are true:
- Disease-free for more than 5 years
- No prior cytotoxic chemotherapy for breast cancer
Prior or concurrent primary endometrial cancer allowed if the following conditions are met:
- Stage no greater than IB
- Less than 3 mm invasion without vascular or lymphatic invasion
- No poorly differentiated subtypes, including papillary serous, clear cell, or other FIGO grade 3 lesions
- Performance status - GOG 0-2
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
- No acute hepatitis
- Creatinine no greater than 1.5 times ULN
- No unstable angina
- No myocardial infarction within the past 6 months
- No evidence of abnormal cardiac conduction (e.g., bundle branch block, heart block) unless stable for the past 6 months
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No greater than grade 1 sensory or motor neuropathy
- No active infection that requires antibiotics
- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
- No severe or ongoing gastrointestinal bleeding that requires blood product support
- See Disease Characteristics
Prior chemotherapy for cancer involving the abdominal cavity or pelvis allowed provided the following are true:
- More than 3 years since prior therapy
- No evidence of recurrent disease
- No prior radiotherapy to any portion of the abdominal cavity or pelvis
Prior radiotherapy for localized breast, head and neck, or skin cancer allowed provided the following are true:
- More than 3 years since prior therapy
- No evidence of recurrent disease
- See Disease Characteristics
- No more than 12 weeks since prior surgical resection
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Arm I
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
|
Gitt IV
Gitt IV
Andre navn:
|
Eksperimentell: Arm II
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8.
|
Gitt IV
Gitt IV
Andre navn:
Gitt IV
Andre navn:
|
Eksperimentell: Arm III
Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I.
|
Gitt IV
Gitt IV
Andre navn:
Andre navn:
|
Eksperimentell: Arm IV
Patients receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3. Treatment continues every 3 weeks for 4 courses.
Patients then receive 4 courses of arm I chemotherapy.
|
Gitt IV
Gitt IV
Andre navn:
Gitt IV
Andre navn:
|
Eksperimentell: Arm V
Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses.
Patients then receive 4 courses of arm I chemotherapy.
Patients with initial unresectable or suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery between courses 4 and 5 of chemotherapy.
|
Gitt IV
Gitt IV
Andre navn:
Gitt IV
Andre navn:
Å bli operert
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Overall Survival
Tidsramme: Up to 9 years
|
Proportion of participants whose overall survival exceeded 5 years.
|
Up to 9 years
|
Progression-free Survival
Tidsramme: From the date of enrollment to first progression or death or last contact, if alive and progression free.
|
Median duration in months of progression free survival.
|
From the date of enrollment to first progression or death or last contact, if alive and progression free.
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of Participants With Observed Adverse Effects (Grade 3 and Above) Assessed by Common Toxicity Criteria Version 2.0
Tidsramme: Up to 9 years
|
Up to 9 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Michael Bookman, Gynecologic Oncology Group
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. Obstet Gynecol. 2019 Feb;133(2):245-254. doi: 10.1097/AOG.0000000000003086. Erratum In: Obstet Gynecol. 2019 Apr;133(4):830.
- Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, Criner GJ, Casaburi R, Connett J, Lazarus SC, Albert R, Woodruff P, Martinez FJ. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1503-8. doi: 10.1164/rccm.201402-0207OC.
- Nickles Fader A, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, Gershenson DM; Gynecologic Oncology Group (GOG)*. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol. 2013 Aug;122(2 Pt 1):225-232. doi: 10.1097/AOG.0b013e31829ce7ec.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer, kjertel og epitel
- Genitale neoplasmer, kvinnelige
- Sykdommer i det endokrine systemet
- Sykdommer i eggstokkene
- Adnexal sykdommer
- Gonadal lidelser
- Neoplasmer i endokrine kjertel
- Karsinom
- Neoplasmer i eggstokkene
- Karsinom, ovarieepitel
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Enzymhemmere
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, fytogene
- Topoisomerase II-hemmere
- Topoisomerasehemmere
- Antibiotika, antineoplastisk
- Topoisomerase I-hemmere
- Gemcitabin
- Karboplatin
- Paklitaksel
- Doxorubicin
- Liposomal doksorubicin
- Topotekan
Andre studie-ID-numre
- GOG-0182 (Annen identifikator: CTEP)
- U10CA027469 (U.S. NIH-stipend/kontrakt)
- NCI-2012-02376 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- SWOG-G0182
- CDR0000068467
- ISRCTN41636183
- MRC-ICON5
- ECOG-G0182
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Primært peritonealt karsinom
-
NORCE Norwegian Research Centre ASNorwegian Labour and Welfare AdministrationFullførtAll International Classification of Primary Care 2 DiagnosesNorge
-
Chulalongkorn UniversityUkjentPeritoneal membransviktThailand
-
University of CincinnatiFullførtFibromyalgi | Juvenil Primary Fibromyalgia Syndrome (JPFS)Forente stater
-
Shanghai Jiao Tong University School of MedicineHar ikke rekruttert ennåPeritoneal skleroseKina
-
Fundacion para la Investigacion Biomedica del Hospital...Fullført
-
Memorial Sloan Kettering Cancer CenterY-mAbs TherapeuticsRekrutteringPeritoneal karsinom | Peritoneal kreft | Desmoplastisk liten rundcellet svulstForente stater
-
University of IowaFullført
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Gateway for Cancer ResearchAktiv, ikke rekrutterendePrimær peritoneal kreft | Eggleder | Epitelial eggstokkForente stater
-
Peking UniversityRekrutteringPrimær peritoneal kreft | Refractory Metastatic Digestive System CarcinomaKina
-
Association Francaise de ChirurgieFullførtKarsinomatose, peritonealFrankrike
Kliniske studier på Karboplatin
-
Samyang Biopharmaceuticals CorporationFullført
-
AkesoRekrutteringAvansert plateepitel, ikke-småcellet lungekreftKina
-
Shanghai Shengdi Pharmaceutical Co., LtdHar ikke rekruttert ennåIkke-plateepitel Ikke-småcellet lungekreftKina
-
Gynecologic Oncology Trial & Investigation ConsortiumJapanese Gynecologic Oncology GroupFullførtEgglederkreft | Epitelial eggstokkreft | Primært peritonealt karsinomJapan, Forente stater, Hong Kong, Korea, Republikken, New Zealand, Singapore
-
Rennes University HospitalFullførtEggstokkreftFrankrike
-
Myrexis Inc.UkjentGlioblastoma MultiformeForente stater
-
The First Affiliated Hospital of Guangzhou Medical...Ukjent
-
Samyang Biopharmaceuticals CorporationFullført
-
National Cancer Institute (NCI)FullførtBrystkreft | EggstokkreftForente stater
-
Sharon SteinMerck Sharp & Dohme LLCAvsluttet